Study ID: Genentech ML28249 (IMPART)_Pulmozyme eRapid Phase 4
Description:

A Phase IV Multicenter, Randomized, Open Label, Two-period Crossover Study in Patients with Cystic Fibrosis to Evaluate the Comparable Efficacy and Safety of Pulmozyme Delivered by the ERapid Nebulizer System

Location:
Sioux Falls Region
Principal Investigator:
James Wallace
Disease:
Stage:
Phase IV

Status:

Active - Open to Accrual

For more information, call or email Bismarck Clinical Research at (701) 323-5760, Fargo and Bemidji Clinical Research at (701) 234-5890, or Sioux Falls Clinical Research at (605) 328-1368.

Back to Clinical Trials list